Our blog

CASE STUDY: Building a US sales team for a startup aligner manufacturer
CASE STUDY: Building a US sales team for a startup aligner manufacturer
by Russell Stones
Posted in Case Studies, Dental, Medical Devices
A startup aligner manufacturer was looking to launch in the US and as part of its ambitious growth plans, the company needed to establish a field sales team. These roles have been critical to the US growth of the startup and one of our candidates is the top performing sales representative in the business.
Read more
Are companies willing to reduce travel for sales and field-based employees?
Are companies willing to reduce travel for sales and field-based employees?
by Naima Morys
Posted in HR, Scientific and Process Technology
Covid-19 has undeniably changed the way we live, work and communicate. For sales, field service and field application employees, travel restrictions have given an insight into a new way of working. As a result, we are seeing an increasing trend of people looking for a better balance, but is this something companies are willing to offer?
Read more
Addressing the post-Brexit hiring challenges of UK Qualified Persons
Addressing the post-Brexit hiring challenges of UK Qualified Persons
by Hawys Evans
Posted in Pharmaceuticals
Before Brexit, the UK could hire QPs from any location within the EU, but now we can only hire QPs based in the UK – resulting in a lack of supply and a rise in day-rates and salaries. We spoke to the Vice President of Quality at a global biotechnology organisation about the challenges of hiring QPs within the UK, and how these might be overcome.
Read more
Should you ever accept a counteroffer?
Should you ever accept a counteroffer?
by Thomas Jones
Posted in Job Search
50% of employees receive a counteroffer when they resign. For your employer, it’s undoubtedly a costly process to recruit your replacement and it is only natural they would try to keep you. But should you ever accept and can the underlying issues that prompted you to explore new opportunities in the first place be resolved by a counteroffer?
Read more
What life science companies should consider for a US expansion
What life science companies should consider for a US expansion
by James Chippindale
Posted in International Expansion, Medical Devices, Pharmaceuticals, Scientific and Process Technology
Are you a life science company looking to expand into the US? To find out more about what you should consider, we interviewed Joanne Farquharson, President & Chief Executive Officer at Foothold America, a company that helps businesses around the world to expand into the US market.
Read more
Attracting and retaining talent during the turnover tsunami
Attracting and retaining talent during the turnover tsunami
by Christine Sands
Posted in HR
In the US, we are beginning to see the start of the predicted ‘turnover tsunami’ and it might not be long until we see something similar across Europe and the UK. But why is this happening and what can employers do to not only retain existing employees but to also attract those individuals looking for a change of career?
Read more
CASE STUDY: Generic Pharma Company’s US Expansion
CASE STUDY: Generic Pharma Company’s US Expansion
by Christine Sands
Posted in Case Studies, International Expansion, Pharmaceuticals
An established pharmaceutical company in Europe that develops, manufactures and markets generic medications planned to continue its growth strategy by opening a new subsidiary to target the US generics market. To develop and commercialise a portfolio of generic drugs to market, the company needed a US General Manager.
Read more
How to manage impostor syndrome
How to manage impostor syndrome
by Naima Morys
Posted in HR
Have you ever felt like you are out of your depth or can’t do the job you’ve been hired to do? Do you worry you will be discovered at any point as a ‘fraud’? You may be suffering from impostor syndrome: a phenomenon where an individual doubts their skills, talents, abilities, and accomplishments in the face of obvious success.
Read more
Will Covid-19 increase US biosimilar adoption in 2021?
Will Covid-19 increase US biosimilar adoption in 2021?
by Ben Conway
Posted in Pharmaceuticals
In 2019, the US biosimilar market was worth $737.2 million and continues to grow with a CAGR of 46.2% forecast for 2020-2027, however many are frustrated at the current rate of adoption in the US. But with increasing healthcare costs and a growing debt from Covid-19, what does the next year hold for biosimilar adoption across the US?
Read more